Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

被引:120
|
作者
Chang, Woo-Sung [1 ,2 ]
Kim, Ji-Yeon [1 ,2 ]
Kim, Yeon-Jeong [1 ,2 ]
Kim, Yun-Sun [1 ,2 ]
Lee, Jung-Mi [1 ,2 ]
Azuma, Miyuki [3 ]
Yagita, Hideo [4 ]
Kang, Chang-Yuil [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
[4] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
来源
JOURNAL OF IMMUNOLOGY | 2008年 / 181卷 / 10期
关键词
D O I
10.4049/jimmunol.181.10.6707
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invariant NKT (iNKT) cells are a distinct subset of T lymphocytes that recognize glycolipid Ags. Upon TCR stimulation, iNKT cells promptly secrete a wide range of cytokines and therefore have been investigated as a target for immunotherapy. However, after primary activation, iNKT cells become hyporesponsive toward their ligand (anergy). The further mechanism behind iNKT cell anergy is poorly understood. We found that a low level of programmed death-1 (PD-1) was constitutively expressed on iNKT cells and that PD-1 expression was increased after stimulation and lasted at least 2 mo. Moreover, not only did blocking of the PD-1/PD ligand 1 (PD-L1) pathway prevent the induction of anergy in iNKT cells, but anergic NKT cells also recovered responsiveness and these "rescued" cells efficiently mediated antitumor immunity. Our findings suggest that the PD-1/PD-L1 interaction is essential for the induction and maintenance of iNKT cell anergy. The Journal of Immunology, 2008,181: 6707-6710.
引用
收藏
页码:6707 / 6710
页数:4
相关论文
共 50 条
  • [31] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [32] Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
    Wang, Tianyu
    Cai, Shi
    Wang, Mingming
    Zhang, Wanheng
    Zhang, Kuojun
    Chen, Dong
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (11) : 7390 - 7403
  • [33] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [34] Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
    Shaabani, Shabnam
    Gadina, Louis
    Surmiak, Ewa
    Wang, Zefeng
    Zhang, Bidong
    Butera, Roberto
    Zarganes-Tzitzikas, Tryfon
    Rodriguez, Ismael
    Kocik-Krol, Justyna
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Domling, Alexander
    Holak, Tad A.
    MOLECULES, 2022, 27 (11):
  • [35] Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents
    Cheng, Binbin
    Ren, Yichang
    Niu, Xiaoge
    Wang, Wei
    Wang, Shuanghu
    Tu, Yingfeng
    Liu, Shuwen
    Wang, Jin
    Yang, Deying
    Liao, Guochao
    Chen, Jianjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (15) : 8338 - 8358
  • [36] Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
    Montasser, Ahmed
    Beaufrere, Aurelie
    Cauchy, Francois
    Bouattour, Mohamed
    Soubrane, Olivier
    Albuquerque, Miguel
    Paradis, Valerie
    HISTOPATHOLOGY, 2021, 79 (01) : 36 - 46
  • [37] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns
    Nishino, Mizuki
    Hatabu, Hiroto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14)
  • [38] Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
    Goto, Hiroyuki
    Sugita, Kazunari
    Yamamoto, Osamu
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (02) : 169 - 173
  • [39] Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts
    Yu, Wesley Y.
    Berger, Timothy G.
    North, Jeffrey P.
    Laszik, Zoltan
    Cohen, Jarish N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (05) : 1127 - 1133
  • [40] Pulmonary Infiltrates in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Okada, A.
    Ota, K.
    Horimoto, K.
    Ibaraki, T.
    Murakami, S.
    Takenaka, H.
    Choh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1079 - S1080